Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.

Amuah JE, Hogan DB, Eliasziw M, Supina A, Beck P, Downey W, Maxwell CJ.

Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):670-9. doi: 10.1002/pds.1946.

PMID:
20583207
2.

Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.

Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD.

Am J Geriatr Pharmacother. 2009 Apr;7(2):74-83. doi: 10.1016/j.amjopharm.2009.04.002.

PMID:
19447360
3.
4.

Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.

Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G.

Arch Gerontol Geriatr Suppl. 2004;(9):297-307.

PMID:
15207427
5.

Impact of rivastigmine use on the risk of nursing home placement in a US sample.

Beusterien KM, Thomas SK, Gause D, Kimel M, Arcona S, Mirski D.

CNS Drugs. 2004;18(15):1143-8.

PMID:
15581384
7.

Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Suh DC, Arcona S, Thomas SK, Powers C, Rabinowicz AL, Shin H, Mirski D.

Drugs Aging. 2004;21(6):395-403.

PMID:
15084141
8.

A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.

Gardette V, Lapeyre-Mestre M, Piau A, Gallini A, Cantet C, Montastruc JL, Vellas B, Andrieu S; ICTUS Group..

CNS Drugs. 2014 Feb;28(2):157-70. doi: 10.1007/s40263-013-0133-3.

PMID:
24408842
9.

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S.

J Am Geriatr Soc. 1999 May;47(5):570-8.

PMID:
10323651
10.

Factors associated with persistence of cholinesterase inhibitor treatments in the elderly.

Pariente A, Pinet M, Moride Y, Merlière Y, Moore N, Fourrier-Réglat A.

Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):680-6. doi: 10.1002/pds.1933.

PMID:
20583209
11.

A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.

Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):361-8. Epub 2005 May 24.

PMID:
15912389
12.
13.

A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.

Wattmo C, Paulsson E, Minthon L, Londos E.

Clin Interv Aging. 2013;8:329-39. doi: 10.2147/CIA.S40087. Epub 2013 Mar 20.

14.

A population-based study of cholinesterase inhibitor use for dementia.

Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman KI, Fischer HD, Sykora K, Shi HS, Rochon PA.

J Am Geriatr Soc. 2007 Oct;55(10):1517-23. Epub 2007 Aug 14.

PMID:
17697100
15.

Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN.

Am J Geriatr Pharmacother. 2006 Jun;4(2):154-60.

PMID:
16860262
16.

Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Kröger E, van Marum R, Souverein P, Egberts T.

Drugs Aging. 2010 Aug 1;27(8):663-75. doi: 10.2165/11538230-000000000-00000.

PMID:
20658794
17.

A population-based study of dosing and persistence with anti-dementia medications.

Brewer L, Bennett K, McGreevy C, Williams D.

Eur J Clin Pharmacol. 2013 Jul;69(7):1467-75. doi: 10.1007/s00228-013-1483-y. Epub 2013 Feb 27.

PMID:
23443628
18.

Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition.

Kogut SJ, El-Maouche D, Abughosh SM.

Pharmacotherapy. 2005 Dec;25(12):1729-35.

PMID:
16305292
19.

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.

Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, Grand A, Monstastruc JL, Vellas B.

CNS Drugs. 2010 May;24(5):431-42. doi: 10.2165/11318010-000000000-00000.

PMID:
20369907
20.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group..

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936

Supplemental Content

Support Center